Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
The paper published in Journal of the American Society of Nephrology (JASN) is an expert opinion on the risks of
Tag: Dexolve
Solubilization of remdesivir by SBECD using ultrasonication
Hielscher Ultrasonics shows on its website how remdesivir solution can be easily prepared by complexation with sulfobutyl ether beta-cyclodextrin using
FDA Approves New KYPROLIS® (SBECD-enabled carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone
Approval Based on the CANDOR and EQUULEUS Studies in Patients With Relapsed/Refractory Multiple Myeloma Amgen today announced the U.S. Food and
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that it
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
Gilead Sciences, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration
Pfizer agrees to manufacture Gilead’s coronavirus drug remdesivir
Pfizer has agreed to manufacture and supply Gilead Sciences’ antiviral drug remdesivir, the pharmaceutical giant announced Friday. The multiyear agreement will support efforts to
Breakthrough Therapy Designation Granted for SBECD-enabled Pevonedistat
Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its SBECD
European Commission secures EU access to Remdesivir for treatment of COVID-19
The European Commission has signed a contract with the pharmaceutical company Gilead to secure treatment doses of Veklury, the brand
Australia’s TGA approves remdesivir while Gilead reports reduced mortality risk
The Therapeutic Goods Administration (TGA) of Australia has awarded provisional approval for the use of Gilead Sciences’ remdesivir (Veklury) to
Gilead prices remdesivir at 390$/vial for governments
Daniel O’Day, Chairman & CEO, Gilead Sciences posted an open letter yesterday, to share pricing indications for Gilead anti-COVID19 treatment,